Curis, Inc.
Index- P/E- EPS (ttm)-0.56 Insider Own0.10% Shs Outstand91.64M Perf Week-10.69%
Market Cap77.05M Forward P/E- EPS next Y-0.73 Insider Trans-5.35% Shs Float85.92M Perf Month-28.00%
Income-51.60M PEG- EPS next Q-0.17 Inst Own81.70% Short Float5.69% Perf Quarter-75.56%
Sales10.50M P/S7.34 EPS this Y19.30% Inst Trans1.09% Short Ratio2.04 Perf Half Y-84.91%
Book/sh0.83 P/B0.95 EPS next Y-6.30% ROA-31.50% Target Price11.80 Perf Year-94.48%
Cash/sh1.24 P/C0.64 EPS next 5Y- ROE-54.00% 52W Range0.75 - 15.60 Perf YTD-83.36%
Dividend- P/FCF- EPS past 5Y26.30% ROI-45.40% 52W High-94.92% Beta3.10
Dividend %- Quick Ratio13.00 Sales past 5Y7.20% Gross Margin95.20% 52W Low5.60% ATR0.10
Employees60 Current Ratio13.00 Sales Q/Q-4.50% Oper. Margin- RSI (14)30.02 Volatility10.59% 10.67%
OptionableYes Debt/Eq0.00 EPS Q/Q-62.00% Profit Margin- Rel Volume1.02 Prev Close0.79
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume2.40M Price0.79
Recom2.00 SMA20-15.92% SMA50-51.03% SMA200-83.10% Volume2,442,415 Change-0.28%
Apr-04-22Downgrade Raymond James Outperform → Mkt Perform
Oct-13-21Initiated Raymond James Outperform $15
Mar-25-21Initiated B. Riley Securities Buy $19
Jul-29-20Initiated Laidlaw Buy $5
Jul-17-20Initiated Cantor Fitzgerald Overweight $4
Oct-24-17Initiated Guggenheim Buy $7
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy $3
Nov-09-15Reiterated ROTH Capital Buy $6 → $5
Aug-11-15Initiated FBR Capital Outperform $6
Jan-22-15Reiterated Oppenheimer Outperform $3 → $5
Jan-21-15Reiterated ROTH Capital Buy $10 → $6
May-09-14Reiterated Oppenheimer Outperform $4.50 → $3
Oct-02-13Initiated Robert W. Baird Outperform $7
Sep-30-13Initiated Chardan Capital Markets Buy $6
Nov-14-12Initiated Stifel Nicolaus Hold
Jan-31-12Reiterated Summer Street Research Buy $5 → $7
Jan-31-12Reiterated Brean Murray Buy $5 → $6
Dec-09-11Initiated Oppenheimer Outperform $6
Oct-06-11Initiated Summer Street Research Buy $5
Sep-22-11Initiated MLV Capital Buy $8.50
May-12-22 10:26AM  
May-11-22 08:59AM  
May-06-22 01:01AM  
May-05-22 06:05PM  
May-04-22 09:35AM  
Apr-28-22 04:00PM  
Apr-21-22 07:28AM  
Apr-12-22 11:57AM  
Apr-11-22 08:00AM  
Apr-07-22 04:01PM  
Apr-05-22 08:00AM  
Apr-04-22 08:53AM  
Mar-07-22 11:03AM  
Mar-04-22 04:40AM  
Feb-25-22 07:30AM  
Feb-24-22 05:40PM  
Feb-17-22 04:00PM  
Jan-31-22 05:38PM  
Jan-20-22 08:00AM  
Jan-14-22 11:33AM  
Jan-07-22 04:01PM  
Jan-06-22 07:00AM  
Jan-03-22 08:00AM  
Dec-22-21 09:41AM  
Dec-15-21 08:00AM  
Dec-14-21 12:00PM  
Dec-06-21 08:00AM  
Nov-29-21 08:54AM  
Nov-24-21 10:00AM  
Nov-16-21 10:00AM  
Nov-10-21 04:32AM  
Nov-09-21 05:45PM  
Nov-08-21 08:00AM  
Nov-04-21 11:11AM  
Nov-02-21 04:01PM  
Oct-25-21 11:37AM  
Oct-17-21 08:35PM  
Oct-07-21 09:00AM  
Oct-06-21 04:01PM  
Sep-20-21 11:50AM  
Sep-08-21 10:15AM  
Sep-02-21 08:00AM  
Aug-06-21 02:27AM  
Aug-04-21 09:01AM  
Aug-03-21 05:25PM  
Jul-27-21 04:01PM  
Jul-07-21 04:01PM  
Jul-06-21 12:52PM  
Jun-28-21 05:17PM  
Jun-26-21 05:50PM  
Jun-25-21 08:00AM  
Jun-22-21 06:35PM  
Jun-21-21 05:37PM  
Jun-20-21 01:53PM  
Jun-17-21 06:42PM  
Jun-16-21 04:50AM  
Jun-14-21 03:26AM  
Jun-11-21 05:54PM  
Jun-08-21 03:16PM  
Jun-04-21 08:00AM  
Jun-01-21 08:00AM  
May-25-21 08:01AM  
May-20-21 09:05AM  
May-13-21 06:42PM  
May-12-21 04:01PM  
May-05-21 08:00AM  
May-04-21 03:00PM  
Apr-19-21 08:00AM  
Apr-07-21 04:01PM  
Apr-06-21 08:00AM  
Mar-25-21 10:17AM  
Mar-19-21 01:42AM  
Mar-17-21 09:05AM  
Mar-16-21 09:00PM  
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation that is in Phase Ia/Ib clinical trial in patients with solid tumors. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. The company was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dentzer James EPresident & CEOJan 31Sale3.073,0949,49964,877Jan 31 05:14 PM
Dentzer James EPresident & CEOJan 27Sale3.182,4067,65167,971Jan 31 05:14 PM